Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)
Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)
复制标题
DOI：
10.1038/bmt.2012.119
复制
发表时间：
2013-02-01
影响因子：
4.8
通讯作者：
Confer, D.
中科院分区：
文献类型：
--
作者：
Halter, J. P.;van Walraven, S. M.;Confer, D.
每年全球进行的同种异体造血干细胞移植的数量持续增加，同时对治疗细胞供体的需求也不断增加。近几十年来，捐助者特征和收集程序发生了重大变化，预计还会发生进一步的变化。有关短期和长期捐赠者结果的信息对于确保最大程度的捐赠者安全性和可用性至关重要。目前的数据主要来自无关的捐赠者，提供了与捐赠相关的频繁早期事件的可靠信息，其中大多数事件的强度为轻度至中度。关于严重不良反应的类型和相对风险的信息更加有限。此外，关于长期捐赠者结果的数据很少。基于这一需求，在一个由积极参与同种异体干细胞捐赠的国际研究小组参与的研讨会上，在全球血液和骨髓移植网络的支持和批准下，制定了关于潜在捐赠者随访的最低数据集的建议。为相关和不相关的捐献者建立标准化的全球随访将能够监测造血细胞捐献的短期和长期安全状况，并为未来的捐献者选择和咨询奠定坚实的基础。骨髓移植 (2013) 48, 220-225; doi：10.1038/bmt.2012.119； 2012 年 7 月 9 日在线发布
The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic cells. Donor characteristics and collection procedures have undergone major changes during recent decades, and further changes are foreseen. Information on short- and long-term donor outcomes is of crucial importance to ensure maximal donor safety and availability. Current data, predominantly from unrelated donors, give reliable information on the frequent early events associated with donation-most of them of mild-to-moderate intensity. Information on the type and relative risk of serious adverse reactions is more limited. Moreover, only few data exist on long-term donor outcome. On the basis of this need, recommendations for a minimum data set for prospective donor follow-up were developed in a workshop with the participation of an international group of investigators actively involved in allogeneic stem cell donation under the auspices of and approved by the Worldwide Network for Blood and Marrow Transplantation. Establishment of a standardized global follow-up for both, related and unrelated, donors will enable monitoring of the short- and long-term safety profiles of hematopoietic cell donation and form a solid basis for future donor selection and counseling. Bone Marrow Transplantation (2013) 48, 220-225; doi:10.1038/bmt.2012.119; published online 9 July 2012